MarketInOut Stock Screener Log In | Sign Up

PaxMedica Inc

OTC • Healthcare • Biotechnology • Quote as of 11/18/2026 09:31
PaxMedica Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeOTC
Market Capitalization0.0884 mln
Float126 mln
Earnings Date08/09/2025

EPS

233
Exceptional

P / E

0.00
Anomalous

Relative Strength

9 / 100
Severely lagging

ROE

-1,047
Deeply negative

ROA

-370
Deeply negative

Business Description

PaxMedica Inc. is a clinical-stage drug development company based in Tarrytown, New York, working on treatments for difficult neurological conditions such as autism spectrum disorder, chronic fatigue syndrome, long COVID-19, and a parasitic brain disease called human African trypanosomiasis. The company's primary focus is on a class of treatments that work by blocking purine receptors, with its furthest-along candidate being PAX-101, an intravenous drug currently in Phase 3 trials, alongside an intranasal version and other related compounds in earlier development. PaxMedica also has a research partnership with PolarMar Health to study emodin as a potential autism treatment, with each company holding separate rights to different forms of the product. Founded in 2018 and formerly called Purinix Pharmaceuticals, the company renamed itself PaxMedica in April 2020.

Key Fundamentals

EPS233
P/E0.00
ROE-1,047
ROIC-416
ROA-370
Interest Cover-1,762
EBITDA, mln-13.49
EV / EBITDA0.29

Quote Details

Last 0.0005
Change 0 (0%)
Open 0.0005
Volume 701
Turnover 0.3505
Average Volume 1,968.33

Financial Ratios

Leverage Ratio1.68
Current Ratio0.36
Price / Book0.00

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -28.57% 5 / 100   
1 Month 0% 70 / 100   
2 Months 25% 96 / 100   
6 Months 400% 100 / 100   
1 Year -99.57% 1 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog